| 13.37 0.06 (0.45%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.15 | 1-year : | 18.86 |
| Resists | First : | 13.82 | Second : | 16.15 |
| Pivot price | 12.49  |
|||
| Supports | First : | 11.64 | Second : | 10.28 |
| MAs | MA(5) : | 12.95 |
MA(20) : | 12.03 |
| MA(100) : | 13.12 |
MA(250) : | 15.02 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 79.7 |
D(3) : | 74.3 |
| RSI | RSI(14): 63.5 |
|||
| 52-week | High : | 20.22 | Low : | 10.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PLRX ] has closed below upper band by 23.4%. Bollinger Bands are 17.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.73 - 13.78 | 13.78 - 13.82 |
| Low: | 13 - 13.06 | 13.06 - 13.11 |
| Close: | 13.28 - 13.37 | 13.37 - 13.45 |
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Fri, 26 Jul 2024
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Wed, 17 Jul 2024
Pliant Therapeutics (NASDAQ:PLRX) Given Buy Rating at Needham & Company LLC - Defense World
Mon, 15 Jul 2024
Pliant Therapeutics Inc. (PLRX) Reports Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial - StreetInsider.com
Mon, 15 Jul 2024
Don't Ignore The Insider Selling In Pliant Therapeutics - Simply Wall St
Sun, 14 Jul 2024
Eric Lefebvre Sells 12,319 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock - American Banking and Market News
Sun, 14 Jul 2024
Mike Ouimette Sells 7,656 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock - American Banking and Market News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.626e+007 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 6,660 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9254e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -78 % |
| Return on Assets (ttm) | 404 % |
| Return on Equity (ttm) | -21.8 % |
| Qtrly Rev. Growth | 248000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -29.46 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.46 |
| Price to Cash Flow | 2.13 |
| Dividend | 0 |
| Forward Dividend | 6.92e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|